liposomal paclitaxel
Phase 3Small molecule
liposomal paclitaxel is one of 62 small molecule programs targeting Neoadjuvant Treatment. It is currently in Phase 3.
2
Indications
6
Total Trials
2
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Nano-Crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Anktiva
SSWOG Cancer Research Network
Phase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
liposomal paclitaxel
SShandong Luye Pharmaceutical Co., Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Paclitaxel2 trials
Non-Small Cell Lung Cancer1 trial
Cancer of the Esophagus1 trial
Esophageal Carcinoma1 trial
Neoadjuvant Treatment1 trial
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Recruiting·—·Phase 3·NCT06102395·272 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for liposomal paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details